{"id":47124,"date":"2022-08-10T05:03:27","date_gmt":"2022-08-10T03:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/"},"modified":"2022-08-10T05:03:27","modified_gmt":"2022-08-10T03:03:27","slug":"jake-r-nunn-joins-board-at-humanetics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/","title":{"rendered":"Jake R. Nunn Joins Board at Humanetics"},"content":{"rendered":"
\n

\nMr. Nunn will add unparalleled pharmaceutical industry insights for Humanetics, which is advancing its lead drug candidate BIO 300 through clinical trials<\/i>\n<\/p>\n

MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry expert Jake R. Nunn to the Company\u2019s Board of Directors.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe can\u2019t overstate the significance of bringing Mr. Nunn onto our Board,\u201d said Ronald J. Zenk, CEO at Humanetics. \u201cHe brings exceptional insights and experience from venture capital and institutional investors, focusing on business growth and maximizing shareholder value. We\u2019re incredibly fortunate to be collaborating with him.\u201d\n<\/p>\n

\nMr. Nunn\u2019s insights will be invaluable as Humanetics\u2019s proprietary drug BIO 300 gains traction for its potential to mitigate the harmful effects of radiation exposure on warfighters, first responders, and healthy tissues in certain cancer patients, as well as improve outcomes for COVID-19 long haulers.\n<\/p>\n

\n\u201cI\u2019m excited to join the Board of Humanetics,\u201d Mr. Nunn said. \u201cAfter more than 25 years of experience in the Life Sciences industry, I\u2019ve pivoted to work as an independent advisor precisely for the opportunity to engage with and support clinical-stage specialty pharma companies like Humanetics to help them position and prepare for their next phase of growth.\u201d\n<\/p>\n

\nBIO 300 is currently in development for multiple applications. BIO 300 is undergoing a phase 2b trial evaluating the clinical utility of the drug to protect lung tissues against the long-term effects of COVID-19, and recently completed a phase 1b\/2a clinical trial in lung cancer patients. BIO 300 has also received significant attention, funding, and research for its potential to mitigate the effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident.\n<\/p>\n

\n\u201cAmong Mr. Nunn\u2019s myriad skills is a remarkable ability to take clinical-stage companies like Humanetics through the necessary steps to maximize its value and strategic options,\u201d added Mr. Zenk. \u201cThe timing is perfect, as we are moving steadily through the clinical trial phases and are approaching the point of proof of efficacy. Mr. Nunn is extremely familiar with the process and the people involved, and we\u2019re grateful to have his expertise on our side.\u201d\n<\/p>\n

\nMr. Nunn has 25 years of experience in the life science industry as an investor, independent director, research analyst and investment banker. He is currently an independent advisor to life science companies and a venture advisor at New Enterprise Associates, or NEA, where he was a partner from 2006-2018. He has served at the executive level of several companies that underwent successful acquisitions, and has particular expertise in later-stage specialty pharmaceuticals. He received an MBA from the Stanford Graduate School of Business and a degree in Economics from Dartmouth College. Mr. Nunn holds the Chartered Financial Analyst designation, is a member of the CFA Society of San Francisco, and recently completed the Stanford GSB Directors\u2019 Consortium executive education program.\n<\/p>\n

\nAbout Humanetics Corporation<\/b>\n<\/p>\n

\nHumanetics is a clinical-stage specialty pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures to prevent harm caused by exposure to radiation, for protective use in cancer radiation therapy, and to guard against the long-term damaging effects of COVID-19. For more information, visit www.humaneticscorp.com.<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJohn Dykstra
\n
Humanetics Corporation
\n
JDykstra@Humaneticscorp.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Mr. Nunn will add unparalleled pharmaceutical industry insights for Humanetics, which is advancing its lead drug candidate BIO 300 through clinical trials MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-47124","format-standard","category-industry"],"yoast_head":"\nJake R. Nunn Joins Board at Humanetics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jake R. Nunn Joins Board at Humanetics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Mr. Nunn will add unparalleled pharmaceutical industry insights for Humanetics, which is advancing its lead drug candidate BIO 300 through clinical trials MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-10T03:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Jake R. Nunn Joins Board at Humanetics\",\"datePublished\":\"2022-08-10T03:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/\"},\"wordCount\":573,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005496\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/\",\"name\":\"Jake R. Nunn Joins Board at Humanetics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005496\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"datePublished\":\"2022-08-10T03:03:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005496\\\/en\\\/821286\\\/21\\\/humlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005496\\\/en\\\/821286\\\/21\\\/humlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/jake-r-nunn-joins-board-at-humanetics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jake R. Nunn Joins Board at Humanetics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jake R. Nunn Joins Board at Humanetics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/","og_locale":"en_US","og_type":"article","og_title":"Jake R. Nunn Joins Board at Humanetics - Pharma Trend","og_description":"Mr. Nunn will add unparalleled pharmaceutical industry insights for Humanetics, which is advancing its lead drug candidate BIO 300 through clinical trials MINNEAPOLIS–(BUSINESS WIRE)–Humanetics Corporation (Humanetics), a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-10T03:03:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Jake R. Nunn Joins Board at Humanetics","datePublished":"2022-08-10T03:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/"},"wordCount":573,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/","url":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/","name":"Jake R. Nunn Joins Board at Humanetics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg","datePublished":"2022-08-10T03:03:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220809005496\/en\/821286\/21\/humlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/jake-r-nunn-joins-board-at-humanetics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Jake R. Nunn Joins Board at Humanetics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47124"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47124\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47124"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}